Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$146.42B | 17x | -1.32 | HK$50.55 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.1% Upside | Upgrade to Pro+ | |
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$102.31B | 25.7x | 0.27 | HK$17.08 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.2% Upside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$63.04B | 6.8x | -1.1 | HK$20.20 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.8% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$62.30B | 19.4x | -0.67 | HK$15.02 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$61.09B | -43.3x | -4.2 | HK$37.20 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.3% Upside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$61.08B | -77.1x | 0.56 | HK$68.75 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.7% Upside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$60.44B | 13.8x | 0.21 | HK$3.31 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.8% Upside | Upgrade to Pro+ | |
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$60.02B | 9.5x | -4.35 | HK$5.13 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.4% Upside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$57.89B | 56.2x | -0.96 | HK$34.20 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.9% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$54.38B | 26.8x | 1.24 | HK$13.94 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.1% Upside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$47.27B | 10.9x | -1.41 | HK$12.72 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.2% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$38.51B | 17.1x | -0.75 | HK$14.50 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.8% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$36.90B | -188x | -2.84 | HK$161.50 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.8% Upside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$33.93B | 8.4x | 0.85 | HK$5.37 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28% Upside | Upgrade to Pro+ | |
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$31.73B | 38.4x | -0.54 | HK$55 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.5% Upside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$29.72B | 48.1x | 0.4 | HK$24.95 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.9% Upside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$29.43B | 8x | -0.66 | HK$18.08 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.4% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$24.57B | -17.8x | -3.59 | HK$11.50 | 6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$23.85B | 17x | 8.34 | HK$26.10 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.9% Upside | Upgrade to Pro+ | |
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$22.50B | -68.2x | 8.16 | HK$26.55 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.9% Upside | Upgrade to Pro+ | |
Shandong Weigao Medical Polymer | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$20.48B | 9.8x | -0.52 | HK$4.47 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.2% Upside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$20.43B | -10.4x | -0.4 | HK$21.50 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$18.56B | 12.5x | -0.22 | HK$7.61 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.3% Upside | Upgrade to Pro+ | |
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$18.46B | 5.9x | 0.2 | HK$10.18 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.9% Upside | Upgrade to Pro+ | |
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$17.75B | -14.4x | 0.1 | HK$7.08 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.7% Upside | Upgrade to Pro+ | |
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$17.50B | -110.8x | 0.62 | HK$4.10 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -14.2% Downside | Upgrade to Pro+ | |
Ping An Healthcare Tech | Hong Kong | Healthcare | Healthcare Providers & Services | HK$16.63B | -688.4x | -6.55 | HK$14.94 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -8.9% Downside | Upgrade to Pro+ | |
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$16.42B | 6.8x | 3.48 | HK$4.70 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.4% Upside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$15.91B | -6.1x | 0.59 | HK$17.14 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.9% Upside | Upgrade to Pro+ | |
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$14.14B | -18,050x | HK$9.22 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -19% Downside | Upgrade to Pro+ |